$DGX
QUEST DIAGNOSTICS INC Stock $dgx

$dgx Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000102207923000136 Filed on July 27, 2023

Income Statement

Concept	2023 Q3	2023 Q2
Revenue	$2.295B	$2.338B
YoY Change	-7.68%	116800.0%
Cost Of Revenue	$1.541B	$1.546B
YoY Change	-4.76%	-4.03%
Gross Profit	$754.0M	$792.0M
YoY Change	-13.13%	-149.22%
Gross Profit Margin	32.85%	33.88%
Selling, General & Admin	$380.0M	$409.0M
YoY Change	-18.1%	-3.08%
% of Gross Profit	50.4%	51.64%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$111.0M	$112.0M
YoY Change	2.78%	4.67%
% of Gross Profit	14.72%	14.14%
Operating Expenses	$380.0M	$437.0M
YoY Change	-18.1%	3.55%
Operating Profit	$342.0M	$355.0M
YoY Change	-12.76%	-8.51%
Interest Expense	$41.00M	-$37.00M
YoY Change	10.81%	-197.37%
% of Operating Profit	11.99%	-10.42%
Other Income/Expense, Net	-$43.00M	$6.000M
YoY Change	4.88%	-109.23%
Pretax Income	$299.0M	$317.0M
YoY Change	-14.81%	-1.86%
Income Tax	$68.00M	$75.00M
% Of Pretax Income	22.74%	23.66%
Net Earnings	$225.0M	$234.0M
YoY Change	-12.11%	0.0%
Net Earnings / Revenue	9.8%	10.01%
Basic Earnings Per Share	$1.99	$2.08
Diluted Earnings Per Share	$1.96	$2.05
COMMON SHARES
Basic Shares Outstanding	112.2M shares	112.0M shares
Diluted Shares Outstanding	114.0M shares	114.0M shares

Balance Sheet

Concept	2023 Q3	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$143.0M	$126.0M
YoY Change	-79.57%	-84.05%
Cash & Equivalents	$143.0M	$126.0M
Short-Term Investments
Other Short-Term Assets	$207.0M	$188.0M
YoY Change	21.05%	20.51%
Inventory	$184.0M	$184.0M
Prepaid Expenses
Receivables	$1.281B	$1.235B
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$1.815B	$1.733B
YoY Change	-22.24%	-28.57%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.830B	$2.425B
YoY Change	7.21%	45.73%
Goodwill	$7.732B	$7.733B
YoY Change	7.54%	7.48%
Intangibles	$1.219B	$1.247B
YoY Change	9.33%	9.0%
Long-Term Investments	$130.0M	$135.0M
YoY Change	-5.8%	-8.16%
Other Assets	$149.0M	$152.0M
YoY Change	12.88%	10.95%
Total Long-Term Assets	$11.67B	$11.69B
YoY Change	7.14%	7.4%
TOTAL ASSETS
Total Short-Term Assets	$1.815B	$1.733B
Total Long-Term Assets	$11.67B	$11.69B
Total Assets	$13.48B	$13.43B
YoY Change	1.96%	0.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.157B	$1.201B
YoY Change	-20.04%	-15.42%
Accrued Expenses	$157.0M	$156.0M
YoY Change	2.61%	0.65%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$304.0M	$518.0M
YoY Change	15100.0%	25800.0%
Total Short-Term Liabilities	$1.618B	$1.875B
YoY Change	1.0%	18.9%
LONG-TERM LIABILITIES
Long-Term Debt	$3.946B	$3.777B
YoY Change	-0.85%	-5.17%
Other Long-Term Liabilities	$874.0M	$1.409B
YoY Change	11.05%	93.54%
Total Long-Term Liabilities	$874.0M	$5.186B
YoY Change	11.05%	612.36%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.618B	$1.875B
Total Long-Term Liabilities	$874.0M	$5.186B
Total Liabilities	$2.492B	$7.176B
YoY Change	4.31%	211.32%
SHAREHOLDERS EQUITY
Retained Earnings	$8.711B	$8.566B
YoY Change	5.42%	5.98%
Common Stock	$2.304B	$2.286B
YoY Change	1.32%	1.51%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$4.570B	$4.587B
YoY Change	7.0%	17.59%
Treasury Stock Shares
Shareholders Equity	$6.425B	$6.249B
YoY Change
Total Liabilities & Shareholders Equity	$13.48B	$13.43B
YoY Change	1.96%	0.85%

Cashflow Statement

Concept	2023 Q3	2023 Q2
OPERATING ACTIVITIES
Net Income	$225.0M	$234.0M
YoY Change	-12.11%	0.0%
Depreciation, Depletion And Amortization	$111.0M	$112.0M
YoY Change	2.78%	4.67%
Cash From Operating Activities	$207.0M	$444.0M
YoY Change	-58.76%	10.45%
INVESTING ACTIVITIES
Capital Expenditures	$105.0M	$104.0M
YoY Change	-188.98%	-236.84%
Acquisitions	$2.000M	$578.0M
YoY Change		57700.0%
Other Investing Activities	-$2.000M	-$578.0M
YoY Change		9533.33%
Cash From Investing Activities	-$107.0M	-$682.0M
YoY Change	-9.32%	731.71%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-83.00M	189.0M
YoY Change	-82.49%	-178.1%
NET CHANGE
Cash From Operating Activities	207.0M	444.0M
Cash From Investing Activities	-107.0M	-682.0M
Cash From Financing Activities	-83.00M	189.0M
Net Change In Cash	17.00M	-49.00M
YoY Change	-118.89%	-162.82%
FREE CASH FLOW
Cash From Operating Activities	$207.0M	$444.0M
Capital Expenditures	$105.0M	$104.0M
Free Cash Flow	$102.0M	$340.0M
YoY Change	-83.55%	-28.87%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6287000000	usd
CY2023Q2	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	77000000	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6415000000	usd
CY2022Q1	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	78000000	usd
CY2022Q2	us-gaap	Temporary Equity Net Income TemporaryEquityNetIncome	2000000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-7000000	usd
CY2022Q2	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	77000000	usd
CY2022Q2	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	13000000	usd
CY2022Q2	dgx	Temporaryequity Noncontrollinginterest Decreasefrom Distributionsto Noncontrolling Interest Holders TemporaryequityNoncontrollinginterestDecreasefromDistributionstoNoncontrollingInterestHolders	3000000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	7000000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	19000000	usd
CY2022Q2	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	200000000	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6450000000	usd
CY2022Q2	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	77000000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6483000000	usd
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	79000000	usd
	dgx	Net Income Loss Excluding Redeemable Noncontrolling Interest NetIncomeLossExcludingRedeemableNoncontrollingInterest	619000000	usd
	us-gaap	Temporary Equity Net Income TemporaryEquityNetIncome	4000000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-9000000	usd
	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	155000000	usd
	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	30000000	usd
	dgx	Temporaryequity Noncontrollinginterest Decreasefrom Distributionsto Noncontrolling Interest Holders TemporaryequityNoncontrollinginterestDecreasefromDistributionstoNoncontrollingInterestHolders	6000000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	14000000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	37000000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	68000000	usd
	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	27000000	usd
	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	550000000	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6450000000	usd
CY2022Q2	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	77000000	usd
	us-gaap	Nature Of Operations NatureOfOperations	DESCRIPTION OF BUSINESS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Background</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span></div> Quest Diagnostics Incorporated and its subsidiaries ("Quest Diagnostics" or the "Company") empower people to take action to improve health outcomes. The Company uses its extensive database of clinical lab results to derive diagnostic insights that reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. The Company's diagnostic information services business ("DIS") provides information and insights based on an industry-leading menu of routine, non-routine and advanced clinical testing and anatomic pathology testing, and other diagnostic information services. The Company provides services to a broad range of customers, including patients, clinicians, hospitals, independent delivery networks ("IDNs"), health plans, employers, consumers, and accountable care organizations ("ACOs"). The Company offers the broadest access in the United States to diagnostic information services through its nationwide network of laboratories, patient service centers and phlebotomists in physician offices and the Company's connectivity resources, including call centers and mobile paramedics, nurses and other health and wellness professionals. The Company is the world's leading provider of diagnostic information services. The Company provides interpretive consultation with one of the largest medical and scientific staffs in the industry. The Company's Diagnostic Solutions businesses ("DS") are the leading provider of risk assessment services for the life insurance industry and offer healthcare organizations and clinicians robust information technology solutions.
	us-gaap	Use Of Estimates UseOfEstimates	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	235000000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	234000000	usd
CY2023Q2	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Diluted ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted	1000000	usd
CY2022Q2	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Diluted ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted	1000000	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	234000000	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	233000000	usd
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	112000000	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	117000000	shares
CY2023Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2000000	shares
CY2022Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2000000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	114000000	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	119000000	shares
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.08
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.00
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.05
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.96
CY2023Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares
CY2022Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1000000	shares
CY2023Q2	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.71
CY2023Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.71
CY2022Q3	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.66
CY2022Q2	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.66
CY2022Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.66
	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	697000000	usd
	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	511000000	usd
CY2023Q2	us-gaap	Business Acquisition Purchase Price Allocation Goodwill Expected Tax Deductible Amount BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount	242000000	usd
CY2023Q2	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	4000000000	usd
CY2022Q4	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	3700000000	usd
CY2022Q4	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.66
CY2023Q1	dgx	Stock Repurchase Program Additional Amount Authorized StockRepurchaseProgramAdditionalAmountAuthorized	1000000000	usd
CY2023Q2	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount1 StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1	1300000000	usd
	us-gaap	Stock Issued During Period Shares Treasury Stock Reissued StockIssuedDuringPeriodSharesTreasuryStockReissued	900000	shares
	us-gaap	Stock Issued During Period Shares Treasury Stock Reissued StockIssuedDuringPeriodSharesTreasuryStockReissued	1200000	shares
CY2023Q2	us-gaap	Depreciation Depreciation	84000000	usd
CY2022Q2	us-gaap	Depreciation Depreciation	80000000	usd
	us-gaap	Depreciation Depreciation	165000000	usd
	us-gaap	Depreciation Depreciation	159000000	usd
CY2023Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	28000000	usd
CY2022Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	27000000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	54000000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	54000000	usd
CY2023Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	112000000	usd
CY2022Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	107000000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	219000000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	213000000	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	39000000	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	38000000	usd
	us-gaap	Interest Expense InterestExpense	76000000	usd
	us-gaap	Interest Expense InterestExpense	75000000	usd
CY2023Q2	us-gaap	Interest And Dividend Income Operating InterestAndDividendIncomeOperating	2000000	usd
CY2022Q2	us-gaap	Interest And Dividend Income Operating InterestAndDividendIncomeOperating	2000000	usd
	us-gaap	Interest And Dividend Income Operating InterestAndDividendIncomeOperating	4000000	usd
	us-gaap	Interest And Dividend Income Operating InterestAndDividendIncomeOperating	2000000	usd
CY2023Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-37000000	usd
CY2022Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-36000000	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-72000000	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-73000000	usd
CY2023Q2	us-gaap	Interest Paid Net InterestPaidNet	48000000	usd
CY2022Q2	us-gaap	Interest Paid Net InterestPaidNet	46000000	usd
	us-gaap	Interest Paid Net InterestPaidNet	80000000	usd
	us-gaap	Interest Paid Net InterestPaidNet	78000000	usd
CY2023Q2	us-gaap	Income Taxes Paid IncomeTaxesPaid	101000000	usd
CY2022Q2	us-gaap	Income Taxes Paid IncomeTaxesPaid	159000000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	134000000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	182000000	usd
CY2023Q2	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	29000000	usd
CY2022Q2	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	23000000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	29000000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	23000000	usd
CY2023Q2	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	81000000	usd
CY2022Q2	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	77000000	usd
CY2023Q2	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	81000000	usd
CY2022Q2	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	77000000	usd
CY2023Q2	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	703000000	usd
CY2022Q2	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	1000000	usd
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	734000000	usd
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	143000000	usd
CY2023Q2	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	36000000	usd
CY2022Q2	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	0	usd
	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	36000000	usd
	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	15000000	usd
CY2023Q2	dgx	Fair Value Of Net Assets Acquired FairValueOfNetAssetsAcquired	667000000	usd
CY2022Q2	dgx	Fair Value Of Net Assets Acquired FairValueOfNetAssetsAcquired	1000000	usd
	dgx	Fair Value Of Net Assets Acquired FairValueOfNetAssetsAcquired	698000000	usd
	dgx	Fair Value Of Net Assets Acquired FairValueOfNetAssetsAcquired	128000000	usd
CY2023Q2	dgx	Merger Consideration Paid Payable Net MergerConsiderationPaidPayableNet	-88000000	usd
CY2022Q2	dgx	Merger Consideration Paid Payable Net MergerConsiderationPaidPayableNet	0	usd
	dgx	Merger Consideration Paid Payable Net MergerConsiderationPaidPayableNet	-88000000	usd
	dgx	Merger Consideration Paid Payable Net MergerConsiderationPaidPayableNet	-18000000	usd
CY2023Q2	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	579000000	usd
CY2022Q2	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	1000000	usd
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	610000000	usd
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	110000000	usd
CY2023Q2	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	1000000	usd
CY2022Q2	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	usd
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	1000000	usd
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	4000000	usd
CY2023Q2	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	578000000	usd
CY2022Q2	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	1000000	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	609000000	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	106000000	usd
CY2023Q2	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	57000000	usd
CY2022Q2	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	21000000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	101000000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	84000000	usd
CY2023Q2	us-gaap	Malpractice Loss Contingency Accrual Undiscounted MalpracticeLossContingencyAccrualUndiscounted	161000000	usd
CY2022Q4	us-gaap	Malpractice Loss Contingency Accrual Undiscounted MalpracticeLossContingencyAccrualUndiscounted	169000000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2338000000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2453000000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4669000000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5064000000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	348000000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	388000000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	653000000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	901000000	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-31000000	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-65000000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-59000000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-126000000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	317000000	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	323000000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	594000000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	775000000	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	75000000	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	77000000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	140000000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	187000000	usd
CY2023Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	7000000	usd
CY2022Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	4000000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	12000000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	35000000	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	249000000	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	250000000	usd
	us-gaap	Profit Loss ProfitLoss	466000000	usd
	us-gaap	Profit Loss ProfitLoss	623000000	usd
CY2023Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	14000000	usd
CY2022Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	16000000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	29000000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	34000000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	235000000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	234000000	usd
	us-gaap	Net Income Loss NetIncomeLoss	437000000	usd
	us-gaap	Net Income Loss NetIncomeLoss	589000000	usd
CY2023Q2	dgx	Revenue From Contract With Customer Excluding Assessed Tax Percent RevenueFromContractWithCustomerExcludingAssessedTaxPercent	1
CY2022Q2	dgx	Revenue From Contract With Customer Excluding Assessed Tax Percent RevenueFromContractWithCustomerExcludingAssessedTaxPercent	1
	dgx	Revenue From Contract With Customer Excluding Assessed Tax Percent RevenueFromContractWithCustomerExcludingAssessedTaxPercent	1
	dgx	Revenue From Contract With Customer Excluding Assessed Tax Percent RevenueFromContractWithCustomerExcludingAssessedTaxPercent	1
CY2023Q2	dgx	Percentageof Net Revenues PercentageofNetRevenues	1
CY2022Q2	dgx	Percentageof Net Revenues PercentageofNetRevenues	1
	dgx	Percentageof Net Revenues PercentageofNetRevenues	1
	dgx	Percentageof Net Revenues PercentageofNetRevenues	1
CY2023Q2	dgx	Percentageof Net Accounts Receivable PercentageofNetAccountsReceivable	1
CY2022Q4	dgx	Percentageof Net Accounts Receivable PercentageofNetAccountsReceivable	1
CY2023Q1	dgx	Stock Repurchase Program Additional Amount Authorized StockRepurchaseProgramAdditionalAmountAuthorized	1000000000	usd

Files In Submission

Name	View Source	Status
0001022079-23-000136-index-headers.html	Edgar Link	pending
0001022079-23-000136-index.html	Edgar Link	pending
0001022079-23-000136.txt	Edgar Link	pending
0001022079-23-000136-xbrl.zip	Edgar Link	pending
dgx-20230630.htm	Edgar Link	pending
dgx-20230630.xsd	Edgar Link	pending
dgx06302023ex101.htm	Edgar Link	pending
dgx06302023ex102.htm	Edgar Link	pending
dgx06302023ex22.htm	Edgar Link	pending
dgx06302023ex311.htm	Edgar Link	pending
dgx-20230630_def.xml	Edgar Link	unprocessable
dgx-20230630_cal.xml	Edgar Link	unprocessable
dgx-20230630_lab.xml	Edgar Link	unprocessable
dgx-20230630_pre.xml	Edgar Link	unprocessable
dgx-20230630_htm.xml	Edgar Link	completed
dgx06302023ex312.htm	Edgar Link	pending
dgx06302023ex321.htm	Edgar Link	pending
dgx06302023ex322.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DGX
QUEST DIAGNOSTICS INC Stock $dgx

2023 Q3 Form 10-Q Financial Statement

#000102207923000136 Filed on July 27, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DGX QUEST DIAGNOSTICS INC Stock $dgx

2023 Q3 Form 10-Q Financial Statement

#000102207923000136 Filed on July 27, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DGX
QUEST DIAGNOSTICS INC Stock $dgx